THRB receptor agonist compound and preparation method and use thereof

1. A compound of Formula (I), or a pharmaceutically acceptable salt thereof,

wherein:

R 1 is selected from the group consisting of hydrogen, cyano, substituted or unsubstituted C 1-6 alkyl, and substituted or unsubstituted C 3-6 cycloalkyl, wherein the substituent is selected from the group consisting of halogen, hydroxy, and C 1-6 alkoxy;

R 2 and R 3 are each independently selected from the group consisting of halogen and substituted or unsubstituted C 1-6 alkyl, wherein the substituent is selected from the group consisting of halogen, hydroxy, and C 1-6 alkoxy;

ring A is a substituted or unsubstituted C 5-10 aromatic ring, wherein the substituent is selected from the group consisting of hydrogen, halogen, hydroxy, —OCF 3 , —NH 2 , —NHC 1-4 alkyl, —N(C 1-4 alkyl) 2 , —CONH 2 , —CONHC 1-4 alkyl, —CON(C 1-4 alkyl) 2 , —NHCOC 1-4 alkyl, C 1-6 alkyl, C 1-6 alkoxy and C 3-6 cycloalkyl, or two substituents are taken together with the carbon to which they are attached to form a ring structure; and

the halogen is selected from the group consisting of F, Cl and Br.

2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein the compound is of Formula (III):

wherein:

R 4 is selected from the group consisting of hydrogen, halogen, hydroxy, —OCF 3 , —NH 2 , —NHC 1-4 alkyl, —N(C 1-4 alkyl) 2 , —CONH 2 , —CONHC 1-4 alkyl, —CON(C 1-4 alkyl) 2 , —NHCOC 1-4 alkyl, C 1-6 alkyl, C 1-6 alkoxy and C 3-6 cycloalkyl;

m is an integer from the range 1 to 4; and

the halogen is selected from the group consisting of F, Cl and Br.

3. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein:

R 4 is selected from the group consisting of hydrogen, halogen, hydroxy, —OCF 3 , C 1-6 alkyl, C 1-6 alkoxy and C 3-6 cycloalkyl; and

m is an integer from the range 1 to 3.

4. The compound of claim 3 , or a pharmaceutically acceptable salt thereof, wherein:

R 4 is selected from the group consisting of hydrogen, halogen and C 1-3 alkyl; and

m is 1 or 2.

5. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein:

R 1 is selected from the group consisting of hydrogen, cyano, and substituted or unsubstituted C 1-6 alkyl, wherein the substituent is selected from the group consisting of halogen, hydroxy, and C 1-6 alkoxy; and

the halogen is selected from the group consisting of F, Cl and Br.

6. The compound of claim 5 , or a pharmaceutically acceptable salt thereof, wherein:

R 1 is selected from the group consisting of cyano and C 1-3 alkyl.

7. The compound of claim 6 , or a pharmaceutically acceptable salt thereof, wherein:

R 1 is cyano.

8. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein:

R 2 and R 3 are each independently selected from the group consisting of F, Cl and Br.

9. The compound of claim 8 , or a pharmaceutically acceptable salt thereof, wherein:

R 2 and R 3 are each Cl.

10. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein the compound is:

11. The compound of claim 10 , or a pharmaceutically acceptable salt thereof, wherein the compound is

12. The compound of claim 10 , or a pharmaceutically acceptable salt thereof, wherein the compound is

13. The compound of claim 10 , or a pharmaceutically acceptable salt thereof, wherein the compound is

14. The compound of claim 10 , or a pharmaceutically acceptable salt thereof, wherein the compound is

15. The compound of claim 10 , or a pharmaceutically acceptable salt thereof, wherein the compound is

16. The compound of claim 10 , or a pharmaceutically acceptable salt thereof, wherein the compound is

17. The compound of claim 10 , or a pharmaceutically acceptable salt thereof, wherein the compound is

18. The compound of claim 10 , or a pharmaceutically acceptable salt thereof, wherein the compound is

19. A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable adjuvant.

20. A method for treating a disease in a subject in need thereof, the method comprising administering to the subject an effective amount of the compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the disease is selected from the group consisting of obesity, hyperlipidemia, hypercholesterolemia, type 2 diabetes, non-alcoholic steatohepatitis (NASH), steatosis of liver, atherosclerosis, hypothyroidism, and thyroid cancer.

21. The method of claim 20 , wherein the disease is selected from the group consisting of obesity, hyperlipidemia, hypercholesterolemia, type 2 diabetes, NASH, steatosis of liver, hypothyroidism, and thyroid cancer.

22. The method of claim 21 , wherein the disease is selected from the group consisting of NASH, hypothyroidism, and thyroid cancer.

23. The pharmaceutical composition of claim 19 , wherein the pharmaceutical composition comprises a therapeutically effective amount of

or a pharmaceutically acceptable salt thereof.

24. The pharmaceutical composition of claim 19 , wherein the pharmaceutical composition comprises a therapeutically effective amount of

or a pharmaceutically acceptable salt thereof.

25. The pharmaceutical composition of claim 19 , wherein the pharmaceutical composition comprises a therapeutically effective amount of

or a pharmaceutically acceptable salt thereof.

26. The method of claim 22 , wherein the disease is NASH.

27. The method of claim 26 , wherein the method comprises administering to the subject an effective amount of

or a pharmaceutically acceptable salt thereof.

28. The method of claim 26 , wherein the method comprises administering to the subject an effective amount of

or a pharmaceutically acceptable salt thereof.

29. The method of claim 26 , wherein the method comprises administering to the subject an effective amount of

or a pharmaceutically acceptable salt thereof.